drugset / Trial / NCT05371496
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
Phase 4
Enrolling by invitation
81 enrolled
Mayo Clinic
United States Department of Defense · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Timeline
- Start
- 2022-09-06
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |